NVO Stock Recent News
NVO LATEST HEADLINES
NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline.
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"), of the important September 30, 2025 lead plaintiff deadline. So What: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Key Points in This Article: Novo Nordisk (NVO) pioneered GLP-1 drugs with Ozempic and Wegovy, but lost ground to Eli Lilly's Mounjaro and Zepbound.
LOS ANGELES , Aug. 22, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). IF YOU SUFFERED A LOSS ON YOUR NOVO NORDISK INVESTMENTS, CLICK HERE BEFORE SEPTEMBER 30, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025.
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international markets and new launches support the outlook. My updated fair value estimate is $67.65, down from $83, reflecting lowered guidance but still offering about 25% upside from current levels. I continue to manage risk with a Put Spread strategy, adapting positions as the stock declines, which has delivered a solid 16-20% ROI even with the stock down ~20%.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).